ArticleACS nano2026
Predictive Screening of Ta
Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The two sides of 2D materials properties: a perspective on balancing air quality applications with environmental and health risks of 2D materials.Environmental science. Advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid development of two-dimensional (2D) MXenes has outpaced our understanding of their pulmonary safety, leaving a critical gap in clinical translation due to inconsistent data from traditional 2D cell cultures. Herein, we developed an immunocompetent three-dimensional (3D) alveolar model comprising A549 epithelial cells, MRC-5 fibroblasts, and THP-1-derived macrophages cultured at the air-liquid interface. This self-organized triculture forms a stratified epithelial-mesenchymal trophic unit with functional surfactant production and cell-cell crosstalk, providing a physiologically relevant platform for the predictive screening of potential nanomedicines. Following thorough characterization, we utilized this system to investigate the therapeutic potential of in-house synthesized Ta
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.